Related Experiment Videos
[Biological markers and exposure to asbestos]
1Service de pneumologie et pathologie professionnelle, CHI de Créteil.
Revue Des Maladies Respiratoires
|July 18, 2000
Summary
Current lung cancer screening biomarkers like CEA, CYFRA21-1, and NSE lack proven value. Further research is needed for novel biomarkers, including those for asbestos-related cancer susceptibility.
Area of Science:
- Oncology
- Biomarker Discovery
- Cancer Screening
Context:
- Established biomarkers for lung cancer screening, including Carcinoembryonic antigen (CEA), CYFRA21-1, and Neuron-specific enolase (NSE), have demonstrated limited diagnostic utility.
- The clinical significance of other potential biomarkers, such as the p53 tumor suppressor gene and antibodies related to oncogenes (e.g., K-ras), remains largely unproven.
Purpose:
- To critically evaluate the current evidence for the effectiveness of known biomarkers in lung cancer screening.
- To identify areas requiring further investigation for the development of reliable cancer biomarkers.
Summary:
- A comprehensive review of existing studies indicates that CEA, CYFRA21-1, and NSE are not valuable for lung cancer screening, individually or in combination.
- The diagnostic potential of biomarkers like p53 and antibodies against oncogene-encoded receptors or p21 protein is still speculative, necessitating further research.
- Additional studies are also required to identify biomarkers for individual susceptibility to asbestos-related cancers, focusing on P450 cytochromes and glutathione-S-transferase.
Impact:
- Highlights the inefficacy of current biomarkers for lung cancer screening, guiding future research directions.
- Emphasizes the need for robust biomarker discovery to improve early cancer detection and risk assessment.
- Underscores the importance of investigating genetic and molecular markers for personalized susceptibility to environmental carcinogens like asbestos.